FATE

Fate Therapeutics' stock price has increased from $1.03 per share on May 8, 2025, to $2.43 as of May 7, 2026. Key events include Q4 2025 earnings report with an EPS of -$0.27, announcement of successful outpatient treatment of autoimmune patients with FT819, preclinical data for FT839 featured at the American Association for Cancer Research Annual Meeting, clinical data from FT819 presented at the Congress of Clinical Rheumatology – East meeting, presentations at the 2026 ASGCT Annual Meeting, and selection of FT819 for the FDA's CMC Development and Readiness Pilot Program. The company is expected to announce its Q1 2026 earnings around May 22, 2026, with projected EPS of -$0.28.